Differential effects of ADAMTS-1, -4, and -5 in the trabecular meshwork

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 12, 2009, Pages 5769-5777

  Keller, Kate E ^a   Bradley, John M ^a   Acott, Ted S ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMTS1 PROTEIN; AGGRECANASE 1; AGGRECANASE 2; CORTACTIN; INTERLEUKIN 1ALPHA; MESSENGER RNA; RECOMBINANT ADAMTS1 PROTEIN; RECOMBINANT AGGRECANASE 1; RECOMBINANT AGGRECANASE 2; RECOMBINANT ENZYME; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ADAM PROTEIN; ADAMTS1 PROTEIN, HUMAN; ADAMTS5 PROTEIN, HUMAN; AGGRECANASE-1; CYTOKINE; PROCOLLAGEN N PROTEINASE; RECOMBINANT PROTEIN;

AGED; ANIMAL TISSUE; ANTERIOR EYE SEGMENT; AQUEOUS HUMOR OUTFLOW; ARTICLE; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; MALE; MECHANICAL STRESS; NONHUMAN; PORK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; ANIMAL; CELL CULTURE; CONFOCAL MICROSCOPY; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; ORGAN CULTURE TECHNIQUE; SWINE; WESTERN BLOTTING;

ADAM PROTEINS; AGED; AGED, 80 AND OVER; ANIMALS; ANTERIOR EYE SEGMENT; BLOTTING, WESTERN; CELLS, CULTURED; CYTOKINES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLAUCOMA; HUMANS; MALE; MICROSCOPY, CONFOCAL; ORGAN CULTURE TECHNIQUES; PROCOLLAGEN N-ENDOPEPTIDASE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRESS, MECHANICAL; SWINE; TRABECULAR MESHWORK;

EID: 73349141409     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-3673     Document Type: Article

References (51)

1. Boland MV, Quigley HA. Risk factors and open-angle glaucoma: classification and application. J Glaucoma. 2007;16:406-418.
2. Acott TS, Kelley MJ. Extracellular matrix in the trabecular mesh-work. Exp Eye Res. 2008;86:543-561.
3. Alexander JP, Samples JR, Van Buskirk EM, Acott TS. Expression of matrix metalloproteinases and inhibitor by human trabecular meshwork. Invest Ophthalmol Vis Sci. 1991;32:172-180.
4. Keller KE, Aga M, Bradley JM, Kelley MJ, Acott TS. Extracellular matrix turnover and outflow resistance. Exp Eye Res. 2009;88: 676-682.
5. Borras T. Gene expression in the trabecular meshwork and the influence of intraocular pressure. Prog Retin Eye Res. 2003;22: 435-463.
6. WuDunn D. The effect of mechanical strain on matrix metallopro-teinase production by bovine trabecular meshwork cells. Curr Eye Res. 2001;22:394-397.
7. Bradley JM, Vranka J, Colvis CM, et al. Effect of matrix metallopro-teinases activity on outflow in perfused human organ culture. Invest Ophthalmol Vis Sci. 1998;39:2649-2658.
8. Alexander JP, Samples JR, Acott TS. Growth factor and cytokine modulation of trabecular meshwork matrix metalloproteinase and TIMP expression. Curr Eye Res. 1998;17:276-285.
9. Bradley JM, Kelley MJ, Zhu X, Anderssohn AM, Alexander JP, Acott TS. Effects of mechanical stretching on trabecular matrix metallo-proteinases. Invest Ophthalmol Vis Sci. 2001;42:1505-1513.
10. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269-285.
11. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007; 8:221-233
12. Aga M, Bradley JM, Keller KE, Kelley MJ, Acott TS. Specialized podosome- or invadopodia-like structures (PILS) for focal trabecular meshwork extracellular matrix turnover. Invest Ophthalmol Vis Sci. 2008;49:5353-5365.
13. Ra HJ, Parks WC. Control of matrix metalloproteinase catalytic activity. Matrix Biol. 2007;26:587-596.
14. Chen WT, Wang JY. Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2, and TIMP-2 localization. Ann N YAcad Sci. 1999;878:361-371.
15. Apte SS. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol. 2004;36:981-985.
16. Porter S, Clark IM, Kevorkian L, Edwards DR. The ADAMTS metalloproteinases. Biochem J. 2005;386:15-27.
17. Tang BL. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol. 2001;33:33-44.
18. Jones GC, Riley GP. ADAMTS proteinases: a multi-domain, multifunctional family with roles in extracellular matrix turnover and arthritis. Arthritis Res Ther. 2005;7:160-169.
19. Nagase H, Kashiwagi M. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther. 2003;5:94-103
20. Bondeson J, Wainwright S, Hughes C, Caterson B. The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol. 2008;26:139-145.
21. Bradley JM, Anderssohn AM, Colvis CM, et al. Mediation of laser trabeculoplasty-induced matrix metalloproteinase expression by IL-1/3 and TNFa. Invest Ophthalmol Vis Sci. 2000;41:422-430.
22. Kelley MJ, Rose AY, Song K, et al. Synergism of TNF and IL-1 in the induction of matrix metalloproteinase-3 in trabecular meshwork. Invest Ophthalmol Vis Sci. 2007;48:2634-2643.
23. Fleenor DL, Shepard AR, Hellberg PE, Jacobson N, Pang IH, Clark AF. TGF/32-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234.
24. Polansky JR, Weinreb RN, Baxter JD, Alvarado J. Human trabecular cells, I: Establishment in tissue culture and growth characteristics. Invest Ophthalmol Vis Sci. 1979;18:1043-1049.
25. Vittal V, Rose A, Gregory KE, Kelley MJ, Acott TS. Changes in gene expression by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci. 2005;46:2857-2868.
26. Keller KE, Kelley MJ, Acott TS. Extracellular matrix gene alternative splicing by trabecular meshwork cells in response to mechanical stretching. Invest Ophthalmol Vis Sci. 2007;48:1164-1172.
27. Keller KE, Bradley JM, Kelley MJ, Acott TS. Effects of modifiers of glycosaminoglycan biosynthesis on outflow facility in perfusion culture. Invest Ophthalmol Vis Sci. 2008;49:2495-2505.
28. Bachmann B, Birke M, Kook D, Eichhorn M, Lutjen-Drecoll E. Ultrastructural and biochemical evaluation of the porcine anterior chamber perfusion model. Invest Ophthalmol Vis Sci. 2006;47: 2011-2020.
29. Inatani M, Tanihara H, Katsuta H, Honjo M, Kido N, Honda Y. Transforming growth factor-beta 2 levels in aqueous humor of glaucomatous eyes. Graefes Arch Clin Exp Ophthalmol. 2001;239: 109-113
30. Gottanka J, Chan D, Eichhorn M, Lutjen-Drecoll E, Ethier CR. Effects of TGF-beta2 in perfused human eyes. Invest Ophthalmol Vis Sci. 2004;45:153-158.
31. Tripathi RC, Li J, Chan WF, Tripathi BJ. Aqueous humor in glaucomatous eyes contains an increased level of TGF-beta 2. Exp Eye Res. 1994;59:723-727.
32. Tumminia SJ, Mitton KP, Arora J, Zelenka P, Epstein DL, Russell P. Mechanical stretch alters the actin cytoskeletal network and signal transduction in human trabecular meshwork cells. Invest Ophthalmol Vis Sci. 1998;39:1361-1371.
33. Gao G, Westling J, Thompson VP, Howell TD, Gottschall PE, Sandy JD. Activation of the proteolytic activity of ADAMTS4 (aggre-canase-1) by C-terminal truncation. J Biol Chem. 2002;277:11034-11041.
34. Gao G, Plaas A, Thompson VP, Jin S, Zuo F, Sandy JD. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated pro-teinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem. 2004;279:10042-10051.
35. Flannery CR, Zeng W, Corcoran C, et al. Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem. 2002;277:42775-42780.
36. Sandy JD, Westling J, Kenagy RD, et al. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem. 2001;276:13372-13378.
37. Zhao X, Russell P. Versican splice variants in human trabecular meshwork and ciliary muscle. Mol Vis. 2005;11:603-608.
38. Fushimi K, Troeberg L, Nakamura H, Lim NH, Nagase H. Functional differences of the catalytic and non-catalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem. 2008;283:6706-6716.
39. Wirtz MK, Bradley JM, Xu H, et al. Proteoglycan expression by human trabecular meshworks. Curr Eye Res. 1997;16:412-421.
40. Wight TN. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol. 2002;14:617-623.
41. Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glyco-proteins of the extracellular matrix. Matrix Biol. 1998;17:1-19.
42. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci. 2000;57:276-289.
43. Geng Y, McQuillan D, Roughley PJ. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol. 2006; 25:484-491.
44. Samples JR, Alexander JP, Acott TS. Regulation of the levels of human trabecular matrix metalloproteinases and inhibitor by in-terleukin-1 and dexamethasone. Invest Ophthalmol Vis Sci. 1993; 34:3386-3395.
45. Hashimoto G, Shimoda M, Okada Y. ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem. 2004;279:32483-32491.
46. Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K. Chon-droitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem. 1986;261:13526-13535.
47. Stanton H, Rogerson FM, East CJ, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005; 434:648-652.
48. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T. Relative messenger RNA expression profiling of collagenases and aggre-canases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum. 2002;46:2648-2657.
49. Kevorkian L, Young DA, Darrah C, et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum. 2004;50:131-141.
50. Glasson SS, Askew R, Sheppard B, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005;434:644-648.
51. Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum. 2004;50:2547-2558.